Clinical Policy: Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix), Filgrastim-aafi (Nivestym)

Reference Number: CP.PHAR.297
Effective Date: 12.01.16
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

Coding Implications

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Filgrastim (Neupogen®) and its biosimilars, filgrastim-sndz (Zarxio®), filgrastim-aafi (Nivestym™), and tbo-filgrastim (Granix®), are human granulocyte colony-stimulating factors.

FDA Approved Indication(s)
Granix is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia (FN).

Neupogen, Nivestym, and Zarxio are indicated to:
- Decrease the incidence of infection, as manifested by FN, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
- Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., FN, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia

Neupogen is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome).

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Neupogen, Zarxio, Nivestym, and Granix are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Chemotherapy-Induced Neutropenia (must meet all):
1. Diagnosis of non-myeloid malignancy or AML;
2. Prescribed for use following myelosuppressive chemotherapy;
3. For Neupogen, Nivestym or Granix requests, member meets one of the following (a or b):
   a. Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced;
      *Prior authorization may be required for Zarxio.
   b. Request is for the treatment associated with Stage IV or metastatic cancer for a State with regulations against step therapy in advanced oncology settings (see Appendix E);
4. For members receiving palliative chemotherapy, provider attestation that chemotherapy dose reduction has been considered;
5. Dose does not exceed 30 mcg/kg per day [IV] or 24 mcg/kg per day [SC] (see Appendix F for dose rounding guidelines).

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Bone Marrow Transplantation (must meet all):
1. Diagnosis of non-myeloid malignancy;
2. Member is undergoing myeloablative chemotherapy followed by BMT;
3. For Neupogen, Nivestym or Granix requests: Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced;
   *Prior authorization may be required for Zarxio.
4. Dose does not exceed 10 mcg/kg per day [IV or SC] (see Appendix F for dose rounding guidelines).

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

C. Peripheral Blood Progenitor Cell Collection (must meet all):
1. Prescribed for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis;
2. The prescribed drug will be initiated before leukapheresis (e.g., prescribed for 6 to 7 days with leukapheresis on days 5, 6 and 7);
3. For Neupogen, Nivestym or Granix requests: Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced;
   *Prior authorization may be required for Zarxio.
4. Request meets one of the following (a or b):
   a. Dose does not exceed 10 mcg/kg per day [IV or SC] (see Appendix F for dose rounding guidelines);
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   *Prescribed regimen must be FDA-approved or recommended by NCCN.

Approved duration:
Medicaid/HIM – 1 month
Commercial – 6 months or to the member’s renewal date, whichever is longer
D. Chronic Neutropenia (must meet all):
   1. Prescribed for use in symptomatic (e.g., fever, infections, oropharyngeal ulcers) severe chronic neutropenia caused by congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia;
   2. For Neupogen, Nivestym or Granix requests: Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced;
      *Prior authorization may be required for Zarxio.
   3. Dose does not exceed: 30 mcg/kg per day [IV] or 24 mcg/kg per day [SC] (see Appendix F for dose rounding guidelines).

Approved duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

E. Acute Radiation Syndrome (must meet all):
   1. Prescribed for use following suspected or confirmed acute exposure to myelosuppressive doses of radiation;
   2. For Neupogen, Nivestym or Granix requests: Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced;
      *Prior authorization may be required for Zarxio.
   3. Dose does not exceed 10 mcg/kg per day [SC] (see Appendix F for dose rounding guidelines).

Approved duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

F. Myelodysplastic Syndrome (off-label) (must meet all):
   1. Diagnosis of myelodysplastic syndrome with symptomatic anemia without del (5q) abnormality;
   2. Current (within the past 30 days) serum erythropoietin level ≤ 500 mU/mL;
   3. For Neupogen, Nivestym or Granix requests: Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced
      *Prior authorization may be required for Zarxio.
   4. Request meets one of the following (a or b):
      a. Dose does not exceed 2 mcg/kg twice a week [SC] (see Appendix F for dose rounding guidelines);
      b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approved duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

G. Other diagnoses/indications
   1. For Neupogen, Nivestym or Granix requests, member meets one of the following (a or b):
      a. Member must use Zarxio, unless contraindicated or clinically significant adverse effects are experienced;
*Prior authorization may be required for Zarxio.

b. Request is for the treatment associated with Stage IV or metastatic cancer for a
   State with regulations against step therapy in advanced oncology settings (see
   Appendix E);

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT
   specifically listed under section III (Diagnoses/Indications for which coverage is
   NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance
   marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met
      initial approval criteria;
   2. Member is responding positively to therapy;
   3. For Neupogen, Nivestym or Granix requests, member meets one of the following (a
      or b):
      a. Medical justification supports inability to use Zarxio (e.g., contraindications to the
         excipients);
         *Prior authorization may be required for Zarxio.
      b. Request is for the treatment associated with Stage IV or metastatic cancer for a
         State with regulations against step therapy in advanced oncology settings (see
         Appendix E);
   4. If request is for a dose increase, request meets one of the following (a or b):
      a. New dose does not exceed the FDA-approved maximum recommended dose for
         the relevant indication (see Appendix F for dose rounding guidelines);
      b. New dose is supported by practice guidelines or peer-reviewed literature for the
         relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):
   1. For Neupogen, Nivestym or Granix requests, member meets one of the following (a
      or b):
      a. Member must use Zarxio, unless contraindicated or clinically significant adverse
         effects are experienced;
         *Prior authorization may be required for Zarxio.
      b. Request is for the treatment associated with Stage IV or metastatic cancer for a
         State with regulations against step therapy in advanced oncology settings (see
         Appendix E);
   2. Currently receiving medication via Centene benefit and documentation supports
      positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

3. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT
   specifically listed under section III (Diagnoses/Indications for which coverage is
   NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance
   marketplace, and CP.PMN.53 for Medicaid.
III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
AML: acute myeloid leukemia  
ANC: absolute neutrophil count  
BMT: bone marrow transplantation  
FDA: Food and Drug Administration  
FN: febrile neutropenia  
G-CSF: granulocyte colony-stimulating factor

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): history of serious allergic reactions
- Boxed warning(s): none reported

Appendix D: General Information
- Zarxio is not recommended in patients requiring direct administration of less than 0.3 mL due to the potential for dosing errors. The spring-mechanism of the needle guard apparatus affixed to the prefilled syringe interferes with the visibility of the graduation markings on the syringe barrel corresponding to 0.1 mL and 0.2 mL. The visibility of these markings is necessary to accurately measure doses of Zarxio less than 0.3 mL (180 mcg).
- Neutropenia is defined as an absolute neutrophil count (ANC) of < 500 neutrophils/mcL or an ANC of < 1,000 neutrophils/mcL and a predicted decline to ≤ 500 neutrophils/mcL over the next 48 hours. Neutropenia can progress to FN, defined as a single temperature of ≥ 38.8 °C orally or ≥ 38.0 °C over 1 hour.
- The development of febrile neutropenia is a common dose-limiting toxicity of many chemotherapy regimens. This risk is directly related to the intensity of the chemotherapy regimen. Chemotherapy regimens that have an incidence of febrile neutropenia greater than 20% in clinical trials in chemotherapy naïve patients are considered by the National Comprehensive Cancer Network (NCCN) panel at high risk. Prophylaxis with myeloid growth factors is recommended at this level of risk (Category 1 recommendation). NCCN Compendium recommend prophylaxis be considered in intermediate-risk (10-20% overall risk of FN) patients (Category 2A recommendation). In addition to chemotherapy regimens, other risk factors such as: treatment-related, patient related, cancer-related, and co-morbidities have also been associated with an increased risk of febrile neutropenia. Therefore, the type of chemotherapy regimen is only one component of the risk assessment.
- For chemotherapy patients, continuing filgrastim until the ANC has reached 10,000/mm³ following the expected chemotherapy-induced neutrophil nadir (as specified in the G-CSF package insert), is known to be safe and effective. However, a shorter duration of
administration that is sufficient to achieve clinically adequate neutrophil recovery is a reasonable alternative, considering issues of patient convenience and cost.\(^5\)

- Evidence supports dose reduction of pegylated interferon according to FDA approved labeling as treatment for neutropenia occurring in hepatitis C patients treated with combination therapy (pegylated interferon + ribavirin). Treatment with filgrastim is not FDA approved or recommended by current hepatitis C treatment guidelines except in patients with decompensated cirrhosis.
- There are insufficient data to support the use of filgrastim to treat febrile neutropenia in patients who have received prophylactic Neulasta.
- In a randomized, double-blind, multi-center safety and efficacy study of 218 breast cancer patients receiving chemotherapy with a high risk of neutropenia, Zarxio was non-inferior to Neupogen on the primary endpoint of duration of severe neutropenia (1.17 days for Zarxio and 1.20 days for Neupogen).
- NCCN guidelines for myelodysplastic syndrome list filgrastim with a category 2A recommendation for use as initial treatment of symptomatic anemia in lower risk disease with no del (5q), serum erythropoietin levels \(\leq 500\) mU/mL, and ring sideroblasts \(\geq 15\%\). Filgrastim may also be considered for the treatment of symptomatic anemia in lower risk disease with serum erythropoietin levels \(\leq 500\) mU/mL, and ring sideroblasts \(< 15\%\) when these is no response to epoetin or darbepoetin alone (category 2A recommendation).
- For patients with a latex allergy, Granix (tbo-filgrastim) and Nivestym (filgrastim-aafi) are considered to be latex free. For Neupogen (filgrastim), and Zarxio (filgrastim-sndz), the presence of latex definitively be ruled out.
- According to the ASCO, 2006 Clinical Practice Guideline for the Use of White Blood Cell Growth Factors, dose reduction or delay remains an appropriate strategy for the palliative treatment of cancer, as there is no evidence that dose maintenance or escalation improves clinically important outcomes in this setting. The 2015 updates to this guideline found no new data supporting the use of colony-stimulating factors (CSFs) to maintain dose-intensity in the treatment of metastatic disease, and the review found no demonstrable benefit in the use of myeloid growth factors to in patients with metastatic lung, small-cell lung, colorectal, hormone-refractory prostate, or breast cancer. To date, there have been no improvements in disease-free or OS reported for any common cancer with the use of CSFs to maintain dose-intensity, instead of dose reduction. The ASCO Panel recognizes that there may be individual patients who will not tolerate effective doses of chemotherapy without CSFs. Medical Oncologists making the decision to use prophylactic MGFs, or not, may need to consider not only the optimal chemotherapy regimen, but also the individual member risk factors and the intention of treatment; that is, curative, prolongation of life, or symptom control and palliation.
- For mobilization of hematopoietic progenitor cells in the autologous setting, NCCN myeloid growth factor treatment guidelines include a dosing range from 10 to 32 mcg/kg/day by subcutaneous injection, in daily or twice-daily dosing, when used as a single-agent growth factor.

### Appendix E: States with Regulations against Redirections in Stage IV or Metastatic Cancer

<table>
<thead>
<tr>
<th>State</th>
<th>Step Therapy Prohibited?</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>FL</td>
<td>Yes</td>
<td>For stage 4 metastatic cancer and associated conditions.</td>
</tr>
<tr>
<td>State</td>
<td>Step Therapy Prohibited?</td>
<td>Notes</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>GA</td>
<td>Yes</td>
<td>For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.</td>
</tr>
<tr>
<td>IA</td>
<td>Yes</td>
<td>For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.</td>
</tr>
<tr>
<td>LA</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer or associated conditions. Exception if “clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.</td>
</tr>
<tr>
<td>OH</td>
<td>Yes</td>
<td><em>Applies to Commercial and HIM requests only</em> For stage 4 metastatic cancer and associated conditions</td>
</tr>
<tr>
<td>PA</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer</td>
</tr>
<tr>
<td>TN</td>
<td>Yes</td>
<td>For advanced metastatic cancer and associated conditions</td>
</tr>
<tr>
<td>TX</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer and associated conditions</td>
</tr>
</tbody>
</table>

**Appendix F: Dose Rounding Guidelines**

<table>
<thead>
<tr>
<th>Weight-based Dose Range</th>
<th>Vial Quantity Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 314.99 mcg</td>
<td>1 vial of 300 mcg/1 mL</td>
</tr>
<tr>
<td>315-503.99 mcg</td>
<td>1 vial of 480 mcg/1.6 mL</td>
</tr>
<tr>
<td>315-629.99 mcg</td>
<td>2 vials of 300 mcg/1 mL</td>
</tr>
<tr>
<td>630-944.99 mcg</td>
<td>3 vials of 300 mcg/1 mL</td>
</tr>
<tr>
<td>945-1,007.99 mcg</td>
<td>2 vials of 480 mcg/1.6 mL</td>
</tr>
<tr>
<td>1,008-1,511.99 mcg</td>
<td>3 vials of 480 mcg/1.6 mL</td>
</tr>
</tbody>
</table>

*This is part of a dose rounding guideline on select drug classes as part of an initiative conducted on a larger scale with multiple references and prescriber feedback.*

**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Drug Name (Neupogen), filgrastim-sndz (Zarxio), filgrastim-aafi (Nivestym)</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| Filgrastim (Neupogen), filgrastim-sndz (Zarxio), filgrastim-aafi (Nivestym) | Chemotherapy-induced neutropenia | 5 mcg/kg SC or IV QD  
Dose may be increased in increments of 5 mcg/kg for each chemotherapy cycle, according to the duration and severity of the ANC nadir  
Do not administer 24 hours before and after chemotherapy | 30 mcg/kg/day [IV] or 24 mcg/kg/day [SC] |
| Chronic neutropenia                                                      | Congenital: 6 mcg/kg SC BID  
Idiopathic or cyclic: 5 mcg/kg SC QD | 30 mcg/kg/day [IV] or 24 mcg/kg/day [SC] |
| BMT                                                                     | 10 mcg/kg IV or SC infusion QD | 10 mcg/kg/day |
### CLINICAL POLICY
Filgrastim, Filgrastim-sndz, Filgrastim-aafi, Tbo-filgrastim

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Peripheral blood progenitor cell collection</td>
<td>10 mcg/kg SC bolus or continuous infusion QD</td>
<td>10 mcg/kg/day</td>
</tr>
<tr>
<td></td>
<td>Patients acutely exposed to myelosuppressive doses of radiation</td>
<td>10 mcg/kg SC QD</td>
<td>10 mcg/kg/day</td>
</tr>
<tr>
<td>Tbo-filgrastim (Granix)</td>
<td>Myelosuppressive chemotherapy</td>
<td>5 mcg/kg SC or IV QD</td>
<td>5 mcg/kg/day</td>
</tr>
</tbody>
</table>

### VI. Product Availability

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filgrastim (Neupogen)</td>
<td>Single-dose prefilled syringes for injection: 300 mcg/0.5 mL, 480 mcg/0.8 mL</td>
</tr>
<tr>
<td></td>
<td>Single-dose vials for injection: 300 mcg/mL, 480 mcg/1.6 mL</td>
</tr>
<tr>
<td>Filgrastim-sndz (Zarxio)</td>
<td>Single-dose prefilled syringes for injection: 300 mcg/0.5 mL, 480 mcg/0.8 mL</td>
</tr>
<tr>
<td>Filgrastim-aafi (Nivestym)</td>
<td>Single-dose prefilled syringes for injection: 300 mcg/0.5 mL, 480 mcg/0.8 mL</td>
</tr>
<tr>
<td></td>
<td>Single-dose vials for injection: 300 mcg/mL, 480 mcg/1.6 mL</td>
</tr>
<tr>
<td>Tbo-filgrastim (Granix)</td>
<td>Single-dose prefilled syringes for injection: 300 mcg/0.5 mL, 480 mcg/0.8 mL</td>
</tr>
<tr>
<td></td>
<td>Single-dose vials for injection: 300 mcg/mL, 480 mcg/1.6 mL</td>
</tr>
</tbody>
</table>

### VII. References


Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1442</td>
<td>Injection, filgrastim (G-CSF), excludes biosimilars, 1 microgram</td>
</tr>
<tr>
<td>J1447</td>
<td>Injection, tbo-filgrastim, 1 microgram</td>
</tr>
<tr>
<td>Q5101</td>
<td>Injection, filgrastim-sndz, biosimilar, 1 microgram</td>
</tr>
<tr>
<td>Q5110</td>
<td>Injection, filgrastim-aafi, biosimilar, 1 microgram</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
<th>Updated template and references. Added continued therapy criteria for severe chronic neutropenia. For AML: changed wording from myelosuppressive chemotherapy from non-myeloid leukemia to induction or consolidation chemotherapy for acute myeloid leukemia per indication.</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.16.17</td>
<td>11.17</td>
<td>3Q 2018 annual review: added HIM line of business; revised maximal dosing for chemotherapy-induced neutropenia and chronic neutropenia per Clinical Pharmacology; removed radiation exposure requirement; added off-label use in myelodysplastic syndrome per NCCN Compendium; references reviewed and updated.</td>
</tr>
<tr>
<td>05.02.18</td>
<td>08.18</td>
<td>No significant changes: revised FDA Approved Indication(s) section for Granix-indication expanded to include pediatric patients ≥ 1 month old per updated FDA labeling.</td>
</tr>
<tr>
<td>09.26.18</td>
<td></td>
<td>No significant changes; revised maximum dosing from 10 mg to 10 mcg for bone marrow transplant criteria set, consistent with prescribing information.</td>
</tr>
<tr>
<td>03.04.19</td>
<td></td>
<td>3Q 2019 annual review: added Nivestym to criteria; added HIM-Medical Benefit line of business, references reviewed and updated.</td>
</tr>
<tr>
<td>05.15.19</td>
<td>08.19</td>
<td>Added latex allergy information to appendix</td>
</tr>
<tr>
<td>07.17.19</td>
<td></td>
<td>Added Commercial line of business per SDC and prior clinical guidance; retire CP.CPA.129.</td>
</tr>
<tr>
<td>09.18.19</td>
<td></td>
<td>Added requirement for redirection to Zarxio to Section II for continued therapy requests; clarified medical justification (rather than</td>
</tr>
<tr>
<td>Reviews, Revisions, and Approvals</td>
<td>Date</td>
<td>P&amp;T Approval Date</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------------------</td>
<td>--------</td>
<td>------------------</td>
</tr>
<tr>
<td>failure) why Zarxio cannot be used is required; removed HIM-Medical Benefit line of business and references to HIM.PA.103 for Granix requests; allowed by-passing of redirection if state regulations do not allow step therapy in Stage IV or metastatic cancer settings.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3Q 2020 annual review: for chemotherapy-induced neutropenia criteria set, added “For members receiving palliative chemotherapy, provider attestation that chemotherapy dose reduction has been considered”; added appendix F: dose rounding guidelines; added reference to appendix F within criteria; references reviewed and updated.</td>
<td>04.30.20</td>
<td>08.20</td>
</tr>
<tr>
<td>For peripheral blood progenitor cell collection indication, added option for off-label dosing per guidelines or peer-reviewed literature.</td>
<td>09.10.20</td>
<td></td>
</tr>
<tr>
<td>Removed AR from appendix E (“For metastatic cancer, unless the preferred drug is consistent with “best practices” (1) used for treatment under (A) FDA-approved indication, or (B) National Comprehensive Cancer Network Drugs &amp; Biologics Compendium; or (2) using evidence-based, peer-reviewed, recognized medical literature. Note – may not require step therapy a second time for same Rx drug”) to minimize misinterpretation.</td>
<td>11.16.20</td>
<td></td>
</tr>
<tr>
<td>Updated appendix E to include Ohio.</td>
<td>02.08.21</td>
<td></td>
</tr>
<tr>
<td>Updated GA language in appendix E.</td>
<td>03.10.21</td>
<td></td>
</tr>
<tr>
<td>Ad Hoc update: applied redirection to preferred filgrastim product to other diagnoses/indications, revised redirection language to match update to “must use” in template, and updated reference for HIM off-label use to HIM.PA.154 (replaces HIM.PHAR.21).</td>
<td>03.15.21</td>
<td></td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage
decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.